Not satisfied with merely providing early stage research support to fight cancer, the Multiple Myeloma Research Foundation has an "end-to-end" strategy for fostering drug development at every stage. The MMRF, headquartered in Norwalk, Conn., has served as midwife to four breakthrough therapies for multiple myeloma: Velcade, Thalomid, Revlimid and Doxil.